Evidence map›Paper›PMID 30716740›Full record

Trial reportPloS one2019

Recent incidence and surgery trends for prostate cancer: Towards an attenuation of overdiagnosis and overtreatment?

Sabrina Jegerlehner, Arnaud Chiolero, Drahomir Aujesky, Nicolas Rodondi, Simon Germann, Isabelle Konzelmann, Jean-Luc Bulliard, NICER Working Group

Open access · goldAbstract readClinical TrialMulticenter Study
In one paragraph

Trial report in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Sabrina JegerlehnerDivision of General Internal Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.ORCID 0000-0002-0868-0608
Arnaud ChioleroDivision of Chronic Diseases, IUMSP, Lausanne University Hospital (CHUV), Lausanne, Switzerland.
Drahomir AujeskyDivision of General Internal Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Nicolas RodondiDivision of General Internal Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Simon GermannDivision of Chronic Diseases, IUMSP, Lausanne University Hospital (CHUV), Lausanne, Switzerland.
Isabelle KonzelmannObservatoire valaisan de la santé (OVS), Sion, Switzerland.
Jean-Luc BulliardDivision of Chronic Diseases, IUMSP, Lausanne University Hospital (CHUV), Lausanne, Switzerland.
NICER Working Group
University of Bern · CHInstitute of Social and Preventive Medicine · CHHôpital du Valais · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundScreening for prostate cancer is frequent in high-income countries, including Switzerland. Notably due to overdiagnosis and overtreatment, various organisations have recently recommended against routine screening, potentially having an impact on incidence, mortality, and surgery rates. Our aim was therefore to examine whether secular trends in the incidence and mortality of prostate cancer, and in prostatectomy rates, have recently changed in Switzerland.

methodsWe conducted a population-based trend study in Switzerland from 1998 to 2012. Cases of invasive prostate cancer, deaths from prostate cancer, and prostatectomies were analysed. We calculated changes in age-standardised prostate cancer incidence rates, stratified by tumor stage (early, advanced), prostate cancer-specific mortality, and prostatectomy rates.

resultsThe age-standardised incidence rate of prostate cancer increased greatly in men aged 50-69 years (absolute mean annual change +4.6/100,000, 95% CI: +2.9 to +6.2) between 1998 and 2002, and stabilised afterwards. In men aged ≥ 70 years, the incidence decreased slightly between 1998 and 2002, and more substantially since 2003. The incidence of early tumor stages increased between 1998 and 2002 only in men aged 50-69 years, and then stabilised, while the incidence of advanced stages remained stable across both age strata. The rate of prostatectomy increased markedly until 2002, more so in the 50 to 69 age range than among men aged ≥ 70 years; it leveled off after 2002 in both age strata. Trends in surgery were driven by radical prostatectomy. Since 1998, the annual age-standardised mortality rate of prostate cancer slightly declined in men aged 50-69 years (absolute mean annual change -0.1/100,000, 95% CI: -0.2 to -0.1) and ≥ 70 years (absolute mean annual change -0.5/100,000, 95% CI: -0.7 to -0.3).

conclusionsThe increases in the incidence of early stage prostate cancer and prostatectomy observed in Switzerland among men younger than 70 years have concomitantly leveled off around 2002/2003. Given the decreasing mortality, these trends may reflect recent changes in screening and clinical workup practices, with a possible attenuation of overdiagnosis and overtreatment.

Indexed as

ProstatectomyRegistriesAgedAge FactorsHumansIncidenceMaleMiddle AgedProstatic NeoplasmsSwitzerland

Identifiers

PMID30716740
PMCPMC6361620
OpenAlexW2913362857

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.